Shire lifts earnings and Baxalta cost saving targets

By Paul Sandle LONDON (Reuters) - Drugmaker Shire upgraded its profit guidance for 2016 on Tuesday, after it hiked the predicted cost saving target for its $32 billion (£24.17 billion) acquisition of rare disease drugs specialist Baxalta and beat forecasts for the second quarter. Shire, which makes drugs to treat hyperactivity as well as rare diseases, reported second-quarter revenue of $2.43 billion while non-GAAP earnings per American Depositary Receipt, its preferred earnings measure, r